0001415889-24-013654.txt : 20240517 0001415889-24-013654.hdr.sgml : 20240517 20240517215619 ACCESSION NUMBER: 0001415889-24-013654 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240515 FILED AS OF DATE: 20240517 DATE AS OF CHANGE: 20240517 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hawryluk Matthew CENTRAL INDEX KEY: 0001754470 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38663 FILM NUMBER: 24962212 MAIL ADDRESS: STREET 1: C/O GRITSTONE ONCOLOGY, INC. STREET 2: 5858 HORTON STREET, SUITE 210 CITY: EMERYVILLE STATE: CA ZIP: 94608 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Gritstone bio, Inc. CENTRAL INDEX KEY: 0001656634 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5959 HORTON STREET, SUITE 300 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: (510) 871-6100 MAIL ADDRESS: STREET 1: 5959 HORTON STREET, SUITE 300 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: Gritstone Oncology, Inc. DATE OF NAME CHANGE: 20151023 4 1 form4-05182024_010513.xml X0508 4 2024-05-15 0001656634 Gritstone bio, Inc. GRTS 0001754470 Hawryluk Matthew C/O GRITSTONE BIO, INC. 5959 HORTON STREET, SUITE 300 EMERYVILLE CA 94608 false true false false EVP, CHIEF BUSINESS OFFICER 0 Common Stock 2024-05-15 4 A 0 19149 0 A 323190 D Common Stock 2024-05-16 4 S 0 9259 0.7483 D 313931 D Stock Option (Right to Buy) 0.75 2024-05-15 4 A 0 180000 0 A 2034-05-14 Common Stock 180000 180000 D Represents Performance Stock Units ("PSUs") granted on March 22, 2024 that were earned by the Reporting Person as a result of the achievement of certain performance criteria as certified by the Issuer's Board of Directors on May 15, 2024. The PSUs vest over one year; 1/2 vested on May 15, 2024, and thereafter the remaining 1/2 will vest on May 15, 2025, subject to the continuing service of the Reporting Person on such vesting date. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock. Includes 273,719 Restricted Stock Units ("RSUs") and PSUs which are subject to vesting. The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of PSUs. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.735 to $0.7616 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option vests as to 1/2 of the total grant on September 30, 2024, with the remainder of grant vesting on September 30, 2025, subject to the continued service of the Reporting Person on each vesting date. /s/ Vassiliki Economides, Attorney-in-Fact for Matthew Hawryluk 2024-05-17